Systems Biology in Biotech & Pharma (eBook)

Abstract.- 1 Introduction: Discovery & Development - New Facet Of Industry, New Tools And Lead Optimization: 1.1 Scope And Content Of This Review.- 1.2 Drug Discovery & Development.- 1.3 Defining Sb:  Key Components.- 1.4  A Brief History Of Systems Biology (Sb), In Terms Of Key Advances.- 1.5 Perspective And Potential Impact Of Systems Biology On Academic Funding And Pharma R&D & Cost Savings.- 2 Discovery: Use Of Systems Biology For Identifying Targets: 2.1 Identifying Targets & Druggability Space.- 2.2 Combinatorial Chemistry Tools.- 2.3 Summarizing.- 3 Integrative Systems Biology I - Biochemistry:  Phase I Lead Discovery & Molecular Interactions.- 3.1 Molecular Screens: Receptor-Ligand (R-L) Interaction & Molecular Modeling.- 3.2 Collateral Efficacy & Permissive Antagonism.- 3.3 Co-Drugging:  Multiple Targets, Combination Therapy & Multistage Targeting.- 3.4 Text Mining For Interactions.- 3.5 Employment Of Biochemical Networks.- 3.6 Overview Of Deterministic Models.- 3.7 Bioinformatics.- 3.8 Summarizing.- 4 Integrative Systems Biology Ii - Molecular Biology:  Phase 2 Lead Discovery & In Silico Screening.- 4.1 Omics.- 4.2 Chemogenomics.- 4.3 Morphogenics.- 4.4 Minimal Phenotype & Synthetic Biology.- 4.5 Reconstructing Biological Networks.- 4.6 Summarizing.- 5. Discovery: Computational Systems Biology (Csb) In Health & And Disease I.- 5.1 Cellular Environment: Network Reconstruction & Inference From Experimental Data.- 5.2 Reconstructing Gene Networks.- 5.3 Data Mining And Heuristic Data Preprocessing Tools.- 5.4 Analysis Of Disease ‘Correlation Networktm’ And Concerted Metabolic Activation – Disease As A Systems Network Property.- 5.5 Challenges For Stem Cells:  Control.- 5.6 Emergent Properties.- 5.7 Computational Systems Biology.- 5.8 Summarizing.- 6 Development:  In Vivo Pharmacology - Systems Biology In Health & Disease Ii.- 6.1 Animal Disease Models.- 6.2 Pheno- And Genotyping.- 6.3 Rna Interference.- 6.4 Pharmacogenomics (Pgn).- 6.5 In Silico Pharmacology:  Future.- 6.6 Summarizing.- 7 Development: Pharmacokinetics – Systems Biology In Health & Disease Iii.- 7.1 Microdosing In Pk.- 7.2 Adaptive Trial Design.- 7.3 Equilibrium Vs. Non-Equilibrium Pk Models.- 7.5 Toxicity Biomarkers.- 7.6 In Silico Toxicity Prediction.- 7.7 Quantitative Pkpd/Tox Modeling.- 7.8 Summarizing.- 8 Development:  Multiscale Csb – Simulation Tools.- 8.1 Defining Csb.- 8.2 Redefining (& Discovering) Emergent Properties At  Higher-Level Hierarchies.- 8.3 Virtual Organs, Disease Models, Virtual Patient.- 8.4 Population Level Model:  Towards Individualized Medicine.- 8.5 Targeting Networks: Towards Organismic, Full-Scale Design.- 8.6 Redefining The Traditional R&D Paradigm.- 8.7 Summarizing.- 9 Development:  Drug Formulation & Delivery.- 9.1 Targeting Concept & Mechanisms.- 9.2 Nanoscale Drug Delivery Systems.- 9.3 Csb At Formulation & Delivery.- 9.4 Summarizing.- 10 Development: Preclinical Model Based Drug Development.- 10.1 Defining Mbdd.- 10.2 Summarizing.- 11 Systems Biology: Impact On Pharma And Biotech.- 11.1 Sb Impact.- 11.2 Key Technologies And Tools Needed For Development Of Systems Biology/Csb.- 11.3 Steps In Systems Biology/Csb.- 11.4 Benefits Of Systems Biology And Csb.- 11.5 Summary.- 12 Acknowledgment.- 13 Bibliography